StonvexLoading…
StonvexStonvexStonvexCore line items from AGNT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.01B | $4.77B | $3.58B | $2.26B |
Operating Income | $-8.79M | $-21.47M | $-8.74M | $-12.75M |
Net Income | $-5.10M | $-22.71M | $-9.82M | $-13.31M |
EPS (Diluted) | $-0.03 | $-0.14 | $-0.06 | $-0.09 |
Total Assets | $467.17M | $442.48M | $458.74M | $481.25M |
Total Liabilities | $211.27M | $199.70M | $223.48M | $262.88M |
Cash & Equivalents | $122.15M | $124.25M | $112.76M | $94.55M |
Free Cash Flow OCF − CapEx | $18.06M | $109.04M | $97.13M | $70.58M |
Shares Outstanding | 164.32M | 161.05M | 158.84M | 157.23M |